Core Viewpoint - A securities class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial reporting during the Class Period from August 7, 2024, to February 24, 2025 [1][2]. Group 1: Allegations Against Maravai - The lawsuit claims that Maravai lacked adequate internal controls over financial reporting related to revenue recognition [2]. - It is alleged that Maravai inaccurately recognized revenue on certain transactions during fiscal 2024 [2]. - The complaint states that Maravai's goodwill was overstated, leading to misleading positive statements about the company's business and prospects [2]. Group 2: Lead Plaintiff Process - Investors in Maravai have until May 5, 2025, to seek appointment as a lead plaintiff representative of the class [3]. - A lead plaintiff acts on behalf of all class members and typically has the largest financial interest in the case [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is handling the class action and encourages affected investors to contact them for more information [4]. - The firm has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4].

NEW YORK, April 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences" or the "Company") (NASDAQ: MRVI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Maravai LifeSciences investors who were adversely affected by alleged securities fraud between August 7, 2024 and February 24, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Maravai LifeSciences To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in Maravai LifeSciences between August 7, 2024 and February 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, ...

THE LEAD PLAINTIFF PROCESS: Maravai investors may, no later than May 5, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also a ...

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United ...

Kessler Topaz Meltzer & Check, LLP encourages Maravai investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: https://www.ktmc.com/new-cases/maravai- lifesciences-holdings-inc?utm_source=PR&utm_medium=link&utm_campaign=mrvi&mktm=r ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: RADNOR, Pa., March 31, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities ...

Shareholders who purchased shares of MRVI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/maravai-lifesciences-holdings-inc-loss-submission-form/? id=139458&from=3 CLASS PERIOD: August 7, 2024 to February 24, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false ...

DEADLINE: May 5, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/maravai-lifesciences-holdings-inc-loss-submission- form/?id=139416&from=4 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of MRVI during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to s ...

RADNOR, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against Maravai LifeSciences Holdings, Inc. (“Maravai”) (NASDAQ: MRVI) on behalf of those who purchased or otherwise acquired Maravai securities between August 7, 2024, and February 24, 2025, inclusive (the “Class Period”). The lead plaintiff deadlin ...

Core Viewpoint - Maravai LifeSciences has faced significant stock price declines due to concerns over its financial reporting and internal controls, leading to a class action lawsuit from investors [1][2][4]. Financial Reporting Issues - On March 18, 2025, Maravai warned investors against relying on its Q2 and Q3 2024 financial reports, stating they would be restated due to improper revenue recognition [3][6]. - The company acknowledged that its disclosure controls and procedures were ineffective, which contributed to the inaccuracies in financial reporting [3][6]. Stock Price Impact - Following the announcement on March 19, 2025, Maravai's shares fell nearly 6%, compounding a previous drop of 21% on February 25, 2025, when the company postponed its Q4 and FY 2024 earnings release [1][5]. - An analyst from Baird downgraded Maravai's rating from outperform to neutral and reduced the price target from $9 to $3 after the February announcement [5]. Class Action Lawsuit - A class action lawsuit has been filed against Maravai, representing investors who purchased securities between August 7, 2024, and February 24, 2025, alleging false and misleading statements regarding financial statements and internal controls [2][4]. - The lawsuit claims that Maravai failed to disclose crucial information about its financial reporting practices, which led to investor losses [4][5]. Revenue Recognition Concerns - Maravai is under scrutiny for potentially recording unearned revenues and overstating goodwill, with specific instances of revenue being inaccurately recognized by approximately $3.9 million in Q2 2024 [5][6]. - The company is currently assessing the adequacy of its internal controls over financial reporting, particularly concerning revenue recognition [6].